Sagemcom Brings on Field First European LTE Cat1 Smart Meter for DSO Enexis in Netherlands
6.7.2017 13:46 | Business Wire
This massive rollout follows successful joined achievements in between Enexis Netbeheer and Sagemcom including final system Integration, Field Test period monitoring and LTE cat1 Radio performance completeness proven by 3rd Party accredited Laboratory.
One and a half year after the award, Sagemcom is delivering to Enexis Netbeheer XS210 single phase Meter and T210 three phase meter for massive rollout.
Through the use of Wireless Mbus communication, Sagemcom ESMR5 smart electricity meters are fully interoperable with all ESMR5 compliant smart gas meters. This new combination of electricity and gas meters will offer real time information on energy consumption in order to reduce energy usage and significantly decrease energy costs for customers.
According to Haico Hangx, Program Manager Smart Meter Development at Enexis Netbeheer: ”We are eager to speed up the roll out with Sagemcom ESMR5 smart electricity meters and we would like to highlight the quality of the partnership with Sagemcom, which has demonstrated its ability to collaborate with Enexis Netbeheer by designing, implementing and producing the smart electricity meters in full compliancy with ESMR5 specifications.”
With this start of massive rollout Sagemcom confirms its leadership in Smart Metering in Europe and its position as top multi technologies smart meter solutions partner. Commenting on this start of rollout, Jean-Philippe Sacriste, Director of Sagemcom Energy department, said: “Sagemcom is very proud to be a long term technology and industrial partner to Enexis. It is also key for us to demonstrate one more time that by choosing Sagemcom our customers have the warranty to fulfill their ambition for Smart Metering roll out and grid management capabilities.”
Based in Rueil Malmaison, Sagemcom, owned by its employees at 30%, is a French company that designs and manufactures communication terminals especially in the Energy, Telecom and Broadband areas. Every day, 250 dedicated people located in Rueil-Malmaison (head office of Sagemcom) contribute to the research, the development, the design and the marketing of meters, data concentrators and software suite for the management of electricity, gas, and water.
About Enexis Netbeheer
Enexis is the regional network operator in the north, east and south of the Netherlands. The company is tasked with the development and construction of energy distribution networks (gas and electricity) and the maintenance and management of these networks. Acting as the link between the customer and the energy supplier, Enexis is responsible for the supply of energy to more than 2.7 million customers. Enexis has 4,500 employees.
A French high-tech group of international dimensions, Sagemcom operates on the broadband (digital home, set-top boxes, Internet routers, telephony and multimedia terminals), smart city (smart meter, smart grid, smart infra, smart sites and smart services), and Internet of Things markets.
With revenue of around 1.5 billion euros, Sagemcom employs 4000 people on five continents and ships every year more than 25 million terminals. Sagemcom aims to remain a world leader in communicating terminals with high added value.
Sagemcom has provided support for its clients for the last 25 years by preparing and implementing their energy management projects, and by deploying secure and sustainable metering solutions, from meters to information systems
Sylvaine COULEUR, 00336 99 37 63 48
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
XILAM Successfully Completes €15m Bond Issue on Euro PP Market27.7.2017 17:42 | Pressemelding
Regulatory News: Xilam (Paris:XIL) today announced the completion of its Euro PP bond issue. The €15 million private placement, repayable at maturity, was subscribed by the NOVI 2 fund managed by Idinvest Partners on behalf of institutional investors and by a European insurer. The bonds have a 6-year maturity, and will be issued in two tranches: The first tranche will be at a variable rate of 6-month EURIBOR* + 400 bp The second tranche will be at a fixed rate of 3.5%. Favourable terms were obtained for the issue with successive drawdown options (limited to 18 months), which will allow the company to optimise the cost of its debt according to its needs. Xilam was advised on the transaction by Euroland Corporate. “We are delighted to have successfully completed this financing transacti
SFL – First-Half 2017 Results27.7.2017 17:00 | Pressemelding
Regulatory News: The interim consolidated financial statements for the six months ended 30 June 2017 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 27 July 2017, at a meeting chaired by Juan-Jose Brugera. First-half business indicators were robust, thanks to the high portfolio occupancy rate, while the period also saw gains in the portfolio's appraisal value and the Company's net asset value. The auditors have completed their review of the interim financial statements. Consolidated data (€ millions)
Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 13:00 | Pressemelding
Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of
Acxiom Launches Connected Spaces27.7.2017 12:30 | Pressemelding
Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative
Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 12:08 | Pressemelding
On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to
European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 11:05 | Pressemelding
Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom